76,577 Shares in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Acquired by Centiva Capital LP

Centiva Capital LP purchased a new stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 76,577 shares of the company’s stock, valued at approximately $273,000. Centiva Capital LP owned approximately 0.12% of Fulcrum Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Dimensional Fund Advisors LP lifted its stake in shares of Fulcrum Therapeutics by 13.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,480,926 shares of the company’s stock valued at $9,182,000 after buying an additional 176,114 shares in the last quarter. Braidwell LP bought a new stake in Fulcrum Therapeutics during the third quarter valued at about $3,817,000. Charles Schwab Investment Management Inc. lifted its position in shares of Fulcrum Therapeutics by 223.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 569,185 shares of the company’s stock valued at $2,032,000 after acquiring an additional 393,202 shares in the last quarter. Assenagon Asset Management S.A. bought a new position in shares of Fulcrum Therapeutics in the second quarter worth about $3,084,000. Finally, Marshall Wace LLP grew its position in shares of Fulcrum Therapeutics by 47.7% during the second quarter. Marshall Wace LLP now owns 333,161 shares of the company’s stock worth $2,066,000 after purchasing an additional 107,588 shares in the last quarter. 89.83% of the stock is currently owned by institutional investors.

Fulcrum Therapeutics Trading Up 5.4 %

FULC stock opened at $4.27 on Thursday. The stock has a market cap of $230.32 million, a PE ratio of -13.06 and a beta of 2.14. Fulcrum Therapeutics, Inc. has a 12 month low of $2.86 and a 12 month high of $13.70. The company has a 50-day moving average price of $3.49 and a 200 day moving average price of $5.98.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Stifel Nicolaus lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and cut their price objective for the company from $22.00 to $3.00 in a report on Thursday, September 12th. Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. HC Wainwright restated a “neutral” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. Cantor Fitzgerald downgraded shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a report on Thursday, September 12th. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a report on Thursday, September 12th. One research analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, Fulcrum Therapeutics currently has an average rating of “Hold” and an average target price of $9.33.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.